Advanced

Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel

Linderholm, B. K.; Lidbrink, E.; Tallroth, E.; Einbeigi, Z.; Svensson, H.; von Wachenfeldt, A.; Norberg, B.; Carlsson, L.; Olsson, M. E. and Bergh, J., et al. (2013) In Breast 22(6). p.1142-1147
Abstract
Background: Several anticancer agents including paclitaxel have an inhibitory effect on angiogenesis. Aims: To compare the overall response rate and time to progression with changes in circulating angiogenic factors during palliative treatment with weekly paclitaxel. Material and methods: Patients with metastatic BC, ECOG 0-2, received weekly paclitaxel, concomitant with trastuzumab if HER2+ BC (n = 7). Circulating vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were determined at base-line and before start of new course. Results: Fifty-five of 63 included patients were evaluable. The overall response rate including stable disease >= 24 weeks (CR + PD + SD) was obtained in 25 of the evaluable patients... (More)
Background: Several anticancer agents including paclitaxel have an inhibitory effect on angiogenesis. Aims: To compare the overall response rate and time to progression with changes in circulating angiogenic factors during palliative treatment with weekly paclitaxel. Material and methods: Patients with metastatic BC, ECOG 0-2, received weekly paclitaxel, concomitant with trastuzumab if HER2+ BC (n = 7). Circulating vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were determined at base-line and before start of new course. Results: Fifty-five of 63 included patients were evaluable. The overall response rate including stable disease >= 24 weeks (CR + PD + SD) was obtained in 25 of the evaluable patients (45%). The median time to progression (TTP) was 5.3 months and overall survival (OS) 16.7 months. Patients with triple negative breast cancer (TNBC) showed a trend towards higher base-line VEGF compared with hormone receptor positive or HER2+ tumours and had shorter TTP. Significant differences in VEGF and bFGF levels at 12 weeks were found between patients with longer versus shorter TTP (VEGF: p = 0.046, bFGF: p = 0.005) and between patients gaining versus lacking clinical benefit (VEGF: p = 0.05, bFGF: p = 0.02). Conclusions: The clinical utility of circulating VEGF may be a useful tool for monitoring treatment efficacy. (C) 2013 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Circulating VEGF and bFGF, Palliative treatment, Weekly paclitaxel
in
Breast
volume
22
issue
6
pages
1142 - 1147
publisher
Churchill Livingstone
external identifiers
  • wos:000326677500022
  • scopus:84887132869
ISSN
1532-3080
DOI
10.1016/j.breast.2013.07.041
language
English
LU publication?
yes
id
851fdf00-5191-4912-92bb-29d6fa0669ee (old id 4196513)
date added to LUP
2014-01-02 12:15:20
date last changed
2019-02-20 05:28:36
@article{851fdf00-5191-4912-92bb-29d6fa0669ee,
  abstract     = {Background: Several anticancer agents including paclitaxel have an inhibitory effect on angiogenesis. Aims: To compare the overall response rate and time to progression with changes in circulating angiogenic factors during palliative treatment with weekly paclitaxel. Material and methods: Patients with metastatic BC, ECOG 0-2, received weekly paclitaxel, concomitant with trastuzumab if HER2+ BC (n = 7). Circulating vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were determined at base-line and before start of new course. Results: Fifty-five of 63 included patients were evaluable. The overall response rate including stable disease >= 24 weeks (CR + PD + SD) was obtained in 25 of the evaluable patients (45%). The median time to progression (TTP) was 5.3 months and overall survival (OS) 16.7 months. Patients with triple negative breast cancer (TNBC) showed a trend towards higher base-line VEGF compared with hormone receptor positive or HER2+ tumours and had shorter TTP. Significant differences in VEGF and bFGF levels at 12 weeks were found between patients with longer versus shorter TTP (VEGF: p = 0.046, bFGF: p = 0.005) and between patients gaining versus lacking clinical benefit (VEGF: p = 0.05, bFGF: p = 0.02). Conclusions: The clinical utility of circulating VEGF may be a useful tool for monitoring treatment efficacy. (C) 2013 Elsevier Ltd. All rights reserved.},
  author       = {Linderholm, B. K. and Lidbrink, E. and Tallroth, E. and Einbeigi, Z. and Svensson, H. and von Wachenfeldt, A. and Norberg, B. and Carlsson, L. and Olsson, M. E. and Bergh, J. and Wilking, Nils and Hatschek, T.},
  issn         = {1532-3080},
  keyword      = {Circulating VEGF and bFGF,Palliative treatment,Weekly paclitaxel},
  language     = {eng},
  number       = {6},
  pages        = {1142--1147},
  publisher    = {Churchill Livingstone},
  series       = {Breast},
  title        = {Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel},
  url          = {http://dx.doi.org/10.1016/j.breast.2013.07.041},
  volume       = {22},
  year         = {2013},
}